Effect of angiotensin-converting enzyme inhibitor on matrix metalloproteinase-9 activity in patients with Kawasaki disease

详细信息    查看全文

• 作者：Nao Inoue ; Shinji Takai ; Denan Jin ; Kenichi Okumura ; Naoyuki Okamura ; Mitsugu Kajiura ; Sosuke Yoshikawa ; Naohisa Kawamura ; Hiroshi Tamai ; Mizuo Miyazaki
• 关键词：Kawasaki disease ; Angiotensin-converting enzyme inhibitor ; Matrix metalloproteinase ; Intravenous immunoglobulin
• 刊名：Clinica Chimica Acta
• 出版年：2010
• 出版时间：2 February 2010
• 年：2010
• 卷：411
• 期：3-4
• 页码：267-269
• 全文大小：129 K

文摘

Background

Matrix metalloproteinase (MMP)-9 is thought to be involved in coronary artery aneurysms (CAAs) in patients with Kawasaki disease (KD); however, MMP-9 inhibitors are not used clinically. This study investigated whether the angiotensin-converting enzyme (ACE) inhibitor captopril could inhibit serum MMP-9 activity using serum from KD patients in an in vitro experiment.

Methods

In 7 KD patients, serum MMP-9 activity was measured using the MMP-9 assay kit 3 times: before and after intravenous immunoglobulin (IVIG) treatment, and during the convalescent phase. The effect of captopril on MMP-9 activity was also assessed using serum obtained before IVIG treatment.

Results

Serum MMP-9 activity was significantly higher during the pre-treatment phase than during the post-treatment and convalescent phases. MMP-9 activity during the pre-treatment phase was dose-dependently inhibited by captopril, and the IC₅₀ for MMP-9 was 500 nM. The potency of captopril for MMP-9 inhibition was comparable to that for ACE inhibition.

Conclusion

ACE inhibitor may be effective for preventing CAA formation in KD patients, especially IVIG non-responders.